Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04210713
Other study ID # HP-00080891
Secondary ID 5K01AA026005-03
Status Completed
Phase Phase 1
First received
Last updated
Start date February 3, 2020
Est. completion date September 20, 2023

Study information

Verified date November 2023
Source University of Maryland, Baltimore
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The objective of this proposal is to advance medication development for alcohol use disorder by examining the efficacy and mechanisms of action of minocycline, a neuroimmune modulator, as a potential treatment. This study has important clinical implications, as the available treatments for alcohol use disorder are only modestly effective and testing novel medications is a high research priority.


Description:

The research objective of this project is to characterize the role of the neuroimmune system in alcohol use disorder (AUD). The proposed study employs a randomized, double-blind, and placebo-controlled design to examine how neuroinflammation, as measured via neuroimaging [e.g., magnetic resonance imaging (MRI)], relates to alcohol craving, neurocognitive impairment (e.g., memory, attention, etc.), and alcohol use in non-treatment seeking individuals with AUD. The study will also determine whether minocycline (MINO), an FDA-approved antibiotic medication, affects any of the above listed measures. In the proposed study, healthy controls (n = 36) and non-treatment seeking individuals with a current Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 AUD diagnosis (n = 36) will be randomized to receive either 200 mg of minocycline per day or placebo for approximately 28 days and complete two laboratory sessions. The first laboratory session will be performed immediately before commencing the medication regimen (day 0) and the second will be completed after taking the medication daily for approximately 28 days. Within each laboratory session, participants will complete a cue reactivity paradigm, neurocognitive performance tasks, and a magnetic resonance imaging (MRI) session. Additionally, blood samples will be drawn on days 0, 7, 14, 21, and 28 of treatment to measure circulating levels of proinflammatory molecules in order to identify the specific immune signaling pathways underlying neuroinflammation in AUD. Clinical labs (e.g., blood chemistry, liver function tests) and adverse events (AEs) will also be assessed at these five visits.


Recruitment information / eligibility

Status Completed
Enrollment 142
Est. completion date September 20, 2023
Est. primary completion date September 20, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 25 Years to 65 Years
Eligibility AUD Group Inclusion Criteria: - Meet DSM-5 diagnostic criteria for an AUD - In the 30-day period before enrollment, consume = 14 and = 7 standard drinks per week for men and women, respectively, AND - In the 30-day period before enrollment, engage in heavy drinking (5 or more drinks for men, 4 or more drinks for women) and = 5 times per month AUD Group Exclusion Criteria: - Currently in treatment for AUD, a history of treatment within the 30 days before enrollment, or currently seeking immediate treatment - Current (last 12 months) DSM-5 diagnosis of substance use disorder for any psychoactive substances other than alcohol and nicotine - Currently prescribed a psychotropic medication for the treatment of schizophrenia spectrum and other psychotic disorders, bipolar and related disorders, depressive disorders, anxiety disorders, and mood disorders. - Lifetime DSM-5 diagnosis of schizophrenia spectrum and other psychotic disorders and bipolar and related disorders - Positive urine toxicology screen for the following substances: cocaine, opiates, amphetamines, methamphetamine, phencyclidine, barbiturates, benzodiazepine, methadone, and tricyclic antidepressants. - Self-reported daily use of cannabidiol (CBD) or opioids (including prescribed) - Serious alcohol withdrawal symptoms as indicated by a score = 10 on the Clinical Institute Withdrawal Assessment for Alcohol-Revised - If female: pregnancy, nursing, or refusal to use reliable method of birth control; if using hormonal contraceptives, refusal to use secondary birth control method - Any autoimmune or inflammatory medical disorder or medical condition that may interfere with safe study participation and/or study aims (e.g., unstable cardiac, renal, or liver disease, uncontrolled hypertension or diabetes) - Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or ?-glutamyl transferase (GGT) = 4 times upper normal limit - Attempted suicide in the past 3 years and/or serious suicidal intention or plan within the past year - Currently on prescription medication that contraindicates use of minocycline, including but not necessarily limited to: isoretinoin, ergot alkaloids, and anti-coagulants. - Previously known hypersensitivity to tetracyclines - Current or recent (within one month) treatment with any antibiotic - Regular use of a prebiotic or probiotic supplement - Claustrophobia or physical issues preventing MRI scan - Presence of a metal device in the body (e.g., pacemaker, infusion pump, aneurysm clip, metal prosthesis or plate) - Current or recent (within 3 months) participation in a clinical trial involving medication administration - Suffered a mild or moderate traumatic brain injury (TBI) within the last 12 months, a severe TBI at any point in their life, or a moderate TBI before the age of 12. - Having below a 6th grade reading level - Within the last 3 months, tested positive for COVID-19 (i.e. the SARS-CoV-2 virus) and experienced common related symptoms. - Any other circumstances that, in the opinion of the investigators, compromises participant safety, ability of the investigators to conduct the study as designed, and/or study integrity. Healthy Control Group Inclusion Criteria: - Does not meet DSM-5 diagnostic criteria for an AUD (current or lifetime) - In the 30-day period before enrollment, consume = 14 and = 7 standard drinks per week for men and women, respectively - Engage in infrequent heavy drinking during the past 6 months (= 2 heavy drinking events in past 6 months) Healthy Control Group Exclusion Criteria: - Lifetime DSM-5 diagnosis of substance use disorder for any psychoactive substances other than nicotine - Self-reported daily use of cannabidiol (CBD) or opioids (including prescribed) - Lifetime DSM-5 diagnosis of schizophrenia spectrum and other psychotic disorders, bipolar and related disorders, depressive disorders, anxiety disorders (panic disorder, agoraphobia, social anxiety, and generalized anxiety), obsessive-compulsive and related disorders, trauma- and stressor-related disorders, feeding and eating disorders (binge eating, anorexia, and bulimia), conduct disorders, and gambling disorder - Positive urine toxicology screen for the following substances: cocaine, opiates, amphetamines, methamphetamine, phencyclidine, barbiturates, benzodiazepine, methadone, and tricyclic antidepressants. - Serious alcohol withdrawal symptoms as indicated by a score = 10 on the Clinical Institute Withdrawal Assessment for Alcohol-Revised - If female: pregnancy, nursing, or refusal to use reliable method of birth control; if using hormonal contraceptives, refusal to use secondary birth control method - Any autoimmune or inflammatory medical disorder or medical condition that may interfere with safe study participation and/or study aims (e.g., unstable cardiac, renal, or liver disease, uncontrolled hypertension or diabetes) - Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or ?-glutamyl transferase (GGT) = 4 times upper normal limit - Attempted suicide in the past 3 years and/or serious suicidal intention or plan within the past year - Currently on prescription medication that contraindicates use of minocycline, including but not necessarily limited to: isoretinoin, ergot alkaloids, and anti-coagulants. - Previously known hypersensitivity to tetracyclines - Current or recent (within one month) treatment with any antibiotic - Regular use of a prebiotic or probiotic supplement - Claustrophobia or physical issues preventing MRI scan - Presence of a metal device in the body (e.g., pacemaker, infusion pump, aneurysm clip, metal prosthesis or plate) - Current or recent (within 3 months) participation in a clinical trial involving medication administration - Suffered a mild or moderate traumatic brain injury (TBI) within the last 12 months, a severe TBI at any point in their life, or a moderate TBI before the age of 12. - Having below a 6th grade reading level - Within the last 3 months, tested positive for COVID-19 (i.e. the SARS-CoV-2 virus) and experienced common related symptoms. - Any other circumstances that, in the opinion of the investigators, compromises participant safety, ability of the investigators to conduct the study as designed, and/or study integrity.

Study Design


Intervention

Drug:
Minocycline
200 mg/day
Sugar pill
Matched placebo

Locations

Country Name City State
United States Maryland Psychiatric Research Center (MPRC) Treatment Research Program (TRP) Catonsville Maryland

Sponsors (2)

Lead Sponsor Collaborator
University of Maryland, Baltimore National Institute on Alcohol Abuse and Alcoholism (NIAAA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Neuroinflammation A multimodal MRI approach consisting of Diffusion Tensor Imaging (DTI) with free water imaging and Magnetic Resonance Spectroscopy (MRS) will be utilized to assess neuroinflammation Change from baseline after 28 days of medication dosing
Primary Cue-Induced Alcohol Craving Participants will listen to a 5-minute guided cue exposure script, during which they are exposed to both a neutral and their preferred alcoholic beverage. Prior to beginning the paradigm and after each cue exposure participants will rate their alcohol craving using the "Alcohol Urge Questionnaire (AUQ)" and cigarette craving using the "Brief Questionnaire on Smoking Urges (BQSU)." Both scales range from 1 to 7 with higher scores reflecting more craving. Change from baseline after 28 days of medication dosing
Primary Alcohol consumption Total drinks consumed assessed using the Timeline Follow Back Change from baseline after 28 days of medication dosing
Primary Verbal Fluency/Language Wechsler Abbreviated Scale of Intelligence (WASI)-Vocabulary, WASI-Similarities, Verbal Fluency (Animals), with higher scores indicating greater intellectual ability. Change from baseline after 28 days of medication dosing
Primary Speed of processing Brief Assessment of Cognition in Schizophrenia (BACS)-Symbol Coding [scored by number of correct numerals (range: 0 -110)] Change from baseline after 28 days of medication dosing
Primary Speed of processing Trail Making Test: Part A (scored by time to complete test with lower scores being better) Change from baseline after 28 days of medication dosing
Primary Speed of processing Grooved Pegboard (scored as a sum of the total time, total number of drops, and the total number of pegs correctly placed in the board with higher scores corresponding to worse performance) Change from baseline after 28 days of medication dosing
Primary Working Memory Wechsler Memory Scale (WMS)-Spatial Span (scored up to 32 correct series), Letter-Number Span (scored up to 30 correct series) Change from baseline after 28 days of medication dosing
Primary Attention Continuous Performance Test Change from baseline after 28 days of medication dosing
Primary Problem Solving/Executive Functioning Wisconsin Card Sorting Test-64 Change from baseline after 28 days of medication dosing
Primary Inhibition/Impulsivity Stop-Signal Reaction Time Change from baseline after 28 days of medication dosing
Primary Verbal Learning Hopkins Verbal Learning Test Change from baseline after 28 days of medication dosing
Primary Visual Learning Brief Visuospatial Memory Test [scoring is as follows, 1) Total recall: The sum of all valid items generated across learning trials 1-3, 2) Delayed recall: The number of valid items generated after a delay (trial 4), 3) Percent retained: Delayed recall score divided by the higher of trial 2 or 3 × 100, and 4) Recognition Discrimination Index: True positive responses minus false positive responses.] Change from baseline after 28 days of medication dosing
Secondary Peripheral Proinflammatory Marker levels Serum level of inflammatory molecules At baseline (day zero) and after 7, 14, and 21 and 28 days of medication dosing
Secondary Alcohol Use Disorder Severity Symptom count from the alcohol module for the Structured Clinical Interview for DSM-5 At baseline (day zero) and after 28 days of medication dosing
Secondary Gut microbiota Gut microbiota from stool samples using the following parameters: 1) diversity and evenness (Shannon, Simpson index) and 2) similarity (phylogenetic UniFrac distance, Jensen-Shannon divergence) At baseline (day zero) and after 7, 14, and 21 and 28 days of medication dosing
See also
  Status Clinical Trial Phase
Completed NCT03995979 - Inflammation and Protein Restriction N/A
Completed NCT03255187 - Effect of Dietary Supplemental Fish Oil in Alleviating Health Hazards Associated With Air Pollution N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Completed NCT03577223 - Egg Effects on the Immunomodulatory Properties of HDL N/A
Completed NCT04383561 - Relationship Between LRG and Periodontal Disease N/A
Active, not recruiting NCT03622632 - Pilot Study to Measure Uric Acid in Traumatized Patients: Determinants and Prognostic Association
Completed NCT06216015 - Exercise Training and Kidney Transplantation N/A
Completed NCT04856748 - Nomogram to Diagnose Prostatic Inflammation (PIN) in Men With Lower Urinary Tract Symptoms
Completed NCT05529693 - Efficacy of a Probiotic Strain on Level of Markers of Inflammation in an Elderly Population N/A
Recruiting NCT05670301 - Flemish Joint Effort for Biomarker pRofiling in Inflammatory Systemic Diseases N/A
Recruiting NCT05415397 - Treating Immuno-metabolic Depression With Anti-inflammatory Drugs Phase 3
Recruiting NCT05775731 - Markers of Inflammation and of the Pro-thrombotic State in Hospital Shift and Day Workers
Recruiting NCT04543877 - WHNRC (Western Human Nutrition Research Center) Fiber Intervention Study Early Phase 1
Completed NCT03859934 - Metabolic Effects of Melatonin Treatment Phase 1
Completed NCT03429920 - Effect of Fermented Soy Based Product on Cardiometabolic Risk Factors N/A
Completed NCT06065241 - Quantifiably Determine if the Botanical Formulation, LLP-01, Has a Significant Clinical Effect on Proteomic Inflammatory Biomarkers and Epigenetic Changes in Healthy, Older Individuals. N/A
Completed NCT05864352 - The Role of Dietary Titanium Dioxide on the Human Gut Microbiome and Health
Completed NCT03318731 - Efficacy and Safety of Fenugreek Extract on Markers of Muscle Damage and Inflammation in Untrained Males N/A
Not yet recruiting NCT06134076 - Comparing Effects of Fermented and Unfermented Pulses and Gut Microbiota N/A
Not yet recruiting NCT06159543 - The Effects of Fresh Mango Consumption on Cardiometabolic Outcomes in Free-living Individuals With Prediabetes N/A